Brean Murray Reiterates a 'Buy' on ImmunoGen (IMGN); Beyond NDA Filing Is a Long List of Upcoming Value-Creating Events
Tweet Send to a Friend
Brean Murray reiterates a 'Buy' on ImmunoGen, Inc. (NASDAQ: IMGN), price target $14.
Brean analyst says shares have been volatile ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Brean analyst says shares have been volatile ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
